| Paul J Zander, MD | |
|
910 E 26th St, Ste 200, Minneapolis, MN 55404-4526 | |
| (612) 884-6300 | |
| (612) 884-6363 |
| Full Name | Paul J Zander |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 35 Years |
| Location | 910 E 26th St, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831158062 | NPI | - | NPPES |
| 1011369 | Other | MN | PREFERRED ONE |
| 26692 | Other | MN | AMERICA'S PPO |
| 31816400 | Medicaid | WI | |
| 3611135 | Other | MN | MEDICA |
| 401803600 | Medicaid | MN | |
| HP11760 | Other | MN | HEALTHPARTNERS |
| 115875 | Other | MN | UCARE MN |
| 18A02ZA | Other | MN | BLUE CROSS BLUE SHIELD MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 33853 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abbott Northwestern Hospital | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Minnesota Oncology Hematology, Pa | 6709799752 | 104 |
News Archive
Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.
Johns Hopkins Hospital lost its coveted spot as the nation's top-ranked hospital for the first time in 22 years, edged out by Boston's Massachusetts General Hospital in the latest analysis by U.S. News & World Report to be released Tuesday. Hopkins still ranked No. 2, and marketing experts said falling one spot will hurt the hospital's ego more than its reputation.
NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.
The number of people with diabetes worldwide will continue to increase at record levels through 2030, with the greatest relative increase in prevalence expected in the Middle Eastern Crescent, sub-Saharan Africa and India, according to a study published in the May issue of Diabetes Care.
› Verified 7 days ago
| Entity Name | Minnesota Oncology Hematology, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528035995 PECOS PAC ID: 6709799752 Enrollment ID: O20031106000626 |
News Archive
Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.
Johns Hopkins Hospital lost its coveted spot as the nation's top-ranked hospital for the first time in 22 years, edged out by Boston's Massachusetts General Hospital in the latest analysis by U.S. News & World Report to be released Tuesday. Hopkins still ranked No. 2, and marketing experts said falling one spot will hurt the hospital's ego more than its reputation.
NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.
The number of people with diabetes worldwide will continue to increase at record levels through 2030, with the greatest relative increase in prevalence expected in the Middle Eastern Crescent, sub-Saharan Africa and India, according to a study published in the May issue of Diabetes Care.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul J Zander, MD 910 E 26th St, Ste 200, Minneapolis, MN 55404-4526 Ph: (612) 884-6300 | Paul J Zander, MD 910 E 26th St, Ste 200, Minneapolis, MN 55404-4526 Ph: (612) 884-6300 |
News Archive
Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.
Johns Hopkins Hospital lost its coveted spot as the nation's top-ranked hospital for the first time in 22 years, edged out by Boston's Massachusetts General Hospital in the latest analysis by U.S. News & World Report to be released Tuesday. Hopkins still ranked No. 2, and marketing experts said falling one spot will hurt the hospital's ego more than its reputation.
NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.
The number of people with diabetes worldwide will continue to increase at record levels through 2030, with the greatest relative increase in prevalence expected in the Middle Eastern Crescent, sub-Saharan Africa and India, according to a study published in the May issue of Diabetes Care.
› Verified 7 days ago
Pascal Frino, M.D Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1 Veterans Dr, Minneapolis, MN 55417 Phone: 612-467-3183 | |
Dr. Ronald Alexander Reilkoff, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Eugenia Shmidt, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 507-284-2511 | |
Daniel Tesfaye Kebed, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 Fax: 612-273-4098 | |
Tenzin Yangchen, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2925 Chicago Ave, Minneapolis, MN 55407 Phone: 612-863-4000 Fax: 763-236-3026 | |
Shelley M Lennox, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 920 E 28th St, Suite 700, Minneapolis, MN 55407 Phone: 612-863-9062 Fax: 612-863-9252 | |
Dr. Markus Meyer, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 |